Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 11/20 | 0.54 |
| ▸ | PARP2 | Q9UGN5 | 3/20 | 0.54 |
| ▸ | PARP1 | P09874 | 2/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | PRKDC | P78527 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7185023 | 1.00 | TNKS (0.54) | TNKSPARP2PARP1DRD2TNKS2 | |
| SCHEMBL16444469 | 0.85 | TNKS (0.62) | TNKSPARP2PARP1TNKS2USP2 | |
| SCHEMBL16444471 | 0.85 | TNKS (0.62) | TNKSPARP2PARP1TNKS2USP2 | |
| SCHEMBL7184086 | 0.83 | ALDH1A1 (0.49) | TNKSPARP2PARP1USP2ALDH1A1 | |
| SCHEMBL7184096 | 0.83 | ALDH1A1 (0.49) | TNKSPARP2PARP1USP2ALDH1A1 | |
| SCHEMBL15289030 | 0.83 | ALDH1A1 (0.56) | TNKSPARP2TNKS2ALDH1A1LMNA | |
| SCHEMBL28522003 | 0.83 | ALDH1A1 (0.56) | TNKSPARP2TNKS2ALDH1A1LMNA | |
| SCHEMBL22605771 | 0.83 | ALDH1A1 (0.56) | TNKSPARP2TNKS2ALDH1A1LMNA | |
| SCHEMBL4433143 | 0.82 | HSD11B1 (0.54) | TNKSPARP2PARP1TNKS2HSD11B1 | |
| SCHEMBL8242664 | 0.81 | TNKS (0.64) | TNKSPARP2PARP1TNKS2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505749-B2 | Quinazolinone compounds and derivatives thereof | AMGEN INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150225396-A1 | Quinazolinone Compounds and Derivatives Thereof | AMGEN INC. | 2015-08-13 | — | — | US | disclosed |
| US-6582351-B1 | Benzimidazole heterocyclic compounds having pharmacological activities, and their use as a medicament for treatment or prevention of diseases mediated by cGMP-PDE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225396-A1 | Quinazolinone Compounds and Derivatives Thereof | TNKS, TPI1, TNKS1BP1 | TNKS 1/4885PARP2 428/4885PARP1 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.